John Nicholson, MD
Colon & Rectal Surgery · East Syracuse, NYNPI 1699872101
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,000 of the $10,894 with a category attached, or 82.6%. Intuitive Surgical accounts for 87.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $9,576 and has fallen 97.6% since, to $231 in 2025.
Across 60 payments — averaging $181.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- TELA Bio, Inc.$412
- Ferring Pharmaceuticals Inc.$179
- Braintree Laboratories, Inc.$108
- Vertex$108
- Merck$98
- plus $485 from 13 others
What the payments were for
- Travel & lodging$2042%
- Food & beverage$1,69016%
- Education$9,00083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $9,504 |
| TELA Bio, Inc. | 6 | $412 |
| Ferring Pharmaceuticals Inc. | 9 | $179 |
| Braintree Laboratories, Inc. | 5 | $108 |
| Vertex | 4 | $108 |
| Merck | 7 | $98 |
| Dexcom, Inc. | 4 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Johnson & Johnson | 1 | $40 |
| Acera Surgical, Inc. | 1 | $35 |
| Axonics, Inc. | 2 | $34 |
| Biom'up France SAS | 1 | $30 |
| Davol Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Fujifilm Healthcare Americas Corporation | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Acelrx Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,894 in reported general payments places this provider in the 80th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 43 | $13,651 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 73 | $12,278 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 93 | $6,060 |
| Mesalamine ErMesalamine | 11 | $5,546 |
| Dextrose 5%-0.45% NaclDextrose 5 %-0.45 % Sod Chlord | 38 | $3,587 |
| Lubiprostone | 12 | $2,002 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 30 | $1,566 |
| Codeine Sulfate | 13 | $737 |
| LoperamideLoperamide Hcl | 15 | $705 |
| Oxycodone Hcl | 21 | $277 |
| Sulfasalazine | 11 | $204 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $106 |
| Metronidazole | 43 | $75 |
| Pantoprazole Sodium | 11 | $66 |
| Clindamycin Hcl | 36 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $179 | $12,27873 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 colon & rectal surgery providers in New York.
Other colon & rectal surgery in East Syracuse
- David NesbittEast Syracuse$15K
- Heitham WadyEast Syracuse$11K
- David RivadeneiraWoodbury$271K
- Jerald WishnerMount Kisco$246K
- Sanghyun KimNew York$154K
- Ziad KronfolWest Nyack$81K
- Lynn OconnorHuntington$63K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- Stephen RauhRochester$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.